32 research outputs found
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
Recommended from our members
Summary and Synthesis Report on Radionuclide Retardation for the Yucca Mountain Site Characterization Project - Yucca Mountain Site Characterization Program Milestone 3784M
Recommended from our members
RoboHound:developing sample collection and preconcentration hardware for a remote trace explosives detection system.
The RoboHound{trademark} Project was a three-year, multiphase project at Sandia National Laboratories to build and refine a working prototype trace explosive detection system as a tool for a commercial robot. The RoboHound system was envisioned to be a tool for emergency responders to test suspicious items (i.e., packages or vehicles) for explosives while maintaining a safe distance. The project investigated combining Sandia's expertise in trace explosives detection with a wheeled robotic platform that could be programmed to interrogate suspicious items remotely for the presence of explosives. All of the RoboHound field tests were successful, especially with regards to the ability to collect and detect trace samples of RDX. The project has gone from remote sampling with human intervention to a fully automatic system that requires no human intervention until the robot returns from a sortie. A proposal is being made for additional work leading towards commercialization
A revision of the genus Rattus (Rodentia, Muridae) in the New Guinean region. Bulletin of the AMNH ; v. 173, article 3
p. 178-336 : ill., maps ; 26 cm.Includes bibliographical references (p. 330-336)."Eleven native and five introduced species of Rattus occur in New Guinea. The native species are represented by 23 subspecies or monotypic species, all of which are endemic, and ally as three major species groups: (1) R. niobe, R. richardsoni, and R. verecundus; (2) R. praetor, R. mordax, R. leucopus, R. steini, R. giluwensis, R. novaeguineae, and R. jobiensis; and (3) R. sordidus. The first species group is largely montane (to 4500 m. altitude) in distribution, the second includes both montane and lowland species, whereas the third, R. sordidus, is restricted to southern lowlands. One new species, R. novaeguineae, and two new subspecies, R. steini baliemensis and R. verecundus vandeuseni, are proposed and described in this revision. Rattus giluwensis, R. jobiensis, and R. steini are elevated to the rank of full species. Among the native species, we recognize two subspecies of Rattus niobe: R. n. niobe (synonyms = Stenomys rufulus and Stenomys niobe stevensi), and R. n. arrogans (synonyms = Rattus niobe haymani (= klossi), Stenomys niobe arfakiensis, and Rattus niobe pococki (= clarae)); Rattus richardsoni as monotypic (synonym = Rattus omichlodes); four subspecies of Rattus verecundus: R. v. verecundus, R. v. mollis (synonym = Rattus verecundus tomba), R. v. unicolor, and R. v. vandeuseni, new subspecies Taylor and Calaby; two subspecies of Rattus praetor: R. p. praetor (synonyms = Rattus praetor mediocris and Rattus purdiensis), and R. p. coenorum (synonyms = Rattus mordax tramitius, Rattus bandiculus, Rattus leucopus utakwa, and Rattus sansapor); two subspecies of Rattus mordax: R. m. mordax and R. m. fergussoniensis; three subspecies of Rattus leucopus: R. l. ringens, R. l. ratticolor, and R. l. dobodurae; four subspecies of Rattus steini: R. s. steini, R. s. foersteri, R. s. hageni (synonym = Rattus rosalinda), and R. s. baliemensis, new subspecies Taylor and Calaby; Rattus giluwensis as monotypic; Rattus novaeguineae, new species Taylor and Calaby as monotypic; Rattus jobiensis as monotypic (synonyms = Rattus owiensis and Rattus biakensis); and two subspecies of Rattus sordidus: R. s. gestri (synonyms = Rattus brachyrhinus and Rattus gestri bunae) and R. s. aramia. The five introduced species are R. exulans, R. nitidus, R. rattus, R. norvegicus, and R. argentiventer, and all are commensals of human beings. Rattus exulans is represented by a single widespread subspecies in New Guinea, R. e. browni, and its establishment here probably antedates that of the others by several thousand years. It is the only introduced species that we assessed in detail taxonomically and regard it as the senior synonym of the following: Mus? echimyoides, Rattus concolor lassacquèrei, Rattus concolor manoquarius, Rattus browni praecelsus, Rattus browni aitape, Rattus browni suffectus, Rattus browni tibicen, Rattus browni gawae, and Rattus rennelli"--P. 179
Recommended from our members
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) 'Marder factors.' Data were included from three 6-week, randomized, double-blind, placebo-controlled studies; a 52-week, randomized, double-blind, placebo-controlled maintenance treatment study; and two 52-week open-label extension (OLEx) studies-all in schizophrenia (DSM-IV-TR criteria). Patients receiving oral brexpiprazole were dosed at 2-4 mg/day (short-term studies) or 1-4 mg/day (long-term studies). At Week 6, least squares mean differences (LSMDs, with 95% confidence limits [CLs]) for brexpiprazole (n = 868) vs placebo (n = 517) were: Positive symptoms: -1.55 (-2.30, -0.80), P < .0001, Cohen's d effect size (ES) = 0.27; Negative symptoms: -1.12 (-1.63, -0.61), P < .0001, ES = 0.29; Disorganized thought: -1.26 (-1.78, -0.74), P < .0001, ES = 0.32; Uncontrolled hostility/excitement: -0.76 (-1.15, -0.37), P = .0002, ES = 0.26; Anxiety/ depression: -0.56 (-0.91, -0.22), P = .0014, ES = 0.22. At last visit of the maintenance study, LSMDs (95% CLs) for brexpiprazole (n = 96) vs placebo (n = 104) were: Positive symptoms: -3.44 (-4.99, -1.89), P < .0001, ES = 0.62; Negative symptoms: -1.23 (-2.52, 0.07), P = .063, ES = 0.27; Disorganized thought: -1.69 (-2.81, -0.56), P = .0035, ES = 0.42; Uncontrolled hostility/excitement: -1.26 (-2.12, -0.39), P = .0046, ES = 0.41; Anxiety/depression: -0.72 (-1.47, 0.03), P = .061, ES = 0.27. In the OLEx studies, improvements were maintained over 58 (6 + 52) weeks of brexpiprazole treatment. In conclusion, these data suggest that brexpiprazole treats the continuum of schizophrenia symptoms, in the short- and long-term. Trial Registration: Data used in this post hoc analysis came from ClinicalTrials.gov identifiers: NCT01396421, NCT01393613, NCT01810380, NCT01668797, NCT01397786, NCT01810783